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“Life can only be understood backwards, but must be lived forwards” 
 
  Søren. Kierkegaard 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Lymfom är ett samlingsnamn för tumörsjukdomar utgående från lymfsystemet, bland vilka 
de follikulära lymfomen tillhör de vanligaste. I Sverige insjuknar ca 250 personer per år. 
Sjukdomsförloppet är i hög grad varierande; ett fåtal patienter tycks tillfriskna spontant och 
en minoritet botas men det stora flertalet avlider så småningom i eller med sin sjukdom, 
efter flera återfall och behandlingsomgångar. Överlevnaden har under senare år förbättrats, 
mycket med hjälp av riktad antikroppsterapi som alternativ eller komplement till strålning 
och cellgifter. Nya läkemedel har tillkommit, med nya verkningsmekanismer, varibland en 
del vänder sig till kroppens eget friska immunförsvar och försöker hjälpa detta att 
identifiera, uppsöka och slutligen döda cancercellerna. Till skillnad från många andra 
lymfomsorter krävs vid follikulärt lymfom inte alltid behandling om patienten är helt 
symptomfri. Alltjämt saknas konsensus kring när behandling skall påbörjas, vilken/vilka 
terapi(er) som är bäst och i vilken ordning dessa bör ges. 
 
Avhandlingen, med flera ingående delprojekt, syftar till att ge ökad kunskap om vilka olika 
faktorer hos den enskilde patienten och hans/hennes specifika lymfom som kan förutsäga 
och påverka sjukdomsutvecklingen och vilken behandlingsstrategi som är den lämpligaste. 
En viktig målsättning är att genom förbättrad individanpassad handläggning uppnå en 
överlevnad lik den som finns hos övriga befolkningen, med minimerade sjukdoms- och 
behandlingsrelaterade komplikationer. 
 
I delarbete I undersökte vi långtidseffekterna av behandling med antikroppen rituximab 
given ensam eller tillsammans med det immunmodulerande läkemedlet interferon-α2a. 
Efter en medianuppföljningstid på 10 år var 234 av de totalt 321 studerade patienterna i 
livet och en tredjedel hade klarat sig så pass väl med denna mildare form av 
lymfombehandling att de aldrig behövt få cellgifter. I delarbete II och delarbete III 
tillämpade vi två olika prognostiska modeller, m7-FLIPI och PRIMA-PI, framtagna på 
patienter som fått traditionell cellgiftsbehandling för att se om de var användbara även på 
den cellgiftsfria gruppen. Det visade sig att endast PRIMA-PI av de två kunde bidra med 
prognostisk information. Utifrån en kombination av endast två variabler kunde modellen 
identifiera en grupp patienter vilkas sjukdom skulle komma att visa sig avsevärt mer 
aggressiv, vilka torde vara betjänt av annan företrädesvis mer intensiv behandling redan 
från början. Delarbete IV handlade om de varierande nivåerna av olika sorters immunceller 
i blodet hos patienter före, under och efter behandling. Även här fick patienterna rituximab 
men istället för kombinationen med interferon gavs det nyare läkemedlet lenalidomid, 
besläktat med det på 60-talet omskrivna medlet Neurosedyn. Blodproverna visade mer eller 
mindre varaktiga förändringar i immuncellernas sammansättning, varav somliga tycktes 
sammanhänga med bättre behandlingseffekt och kanske i förlängningen förbättrad 
överlevnad. 
  
ABSTRACT 
 
Follicular lymphoma (FL) is a heterogeneous group of malignancies within the adaptive 
immune system. The clinical course is highly variable. Treatment includes different 
chemotherapy regimens as well as the anti-CD20 monoclonal antibody rituximab which has 
significantly improved the prognosis for patients with all types of B cell lymphomas. The 
majority of patients with FL respond well to therapy but eventually relapse and generalized 
disease is still considered incurable. On the other hand, a substantial number appear to have 
such an indolent disease that the benefit from treatment is unclear. In the clinical setting 
one challenge is to identiy FL patients in need of therapy upfront as opposed to those who 
can be managed with active expectancy. Seemingly of importance in addition to the clinical 
status of the host are characteristics of the tumour cells as well as of the immune cells in the 
surrounding microenvironment. A greater understanding of the complex intra- and inter-
cellular signaling provides new potential targets for therapeutical intervention. 
 
The aim of this thesis was to gain increased insight in clinical and immunological factors of 
prognostic importance, in indolent lymphoma in general and in FL in particular. This was 
done by investigation of the long-term outcome in patients treated with rituximab-based 
immunotherapy and of the validity of the prognostic tools developed in patients receiving 
standard chemotherapy-based treatment. We also made a study on the interaction of 
rituximab and the immunomodulator lenalidomide with the healthy immune system during 
therapy. 
 
In paper I we evaluated the late effects of rituximab monotherapy and rituximab with 
interferon-α2a in 321 previously untreated symptomatic indolent lymphoma patients. After 
a median follow-up of 10 years more than one third had never required chemotherapy and 
73% were still alive. 
 
In papers II and III we investigated the two prognostic models m7-FLIPI and PRIMA-PI, 
both recently developed on cohorts of FL patients treated with a combination of rituximab 
and CHOP/CVP. The clinicogenetic m7-FLIPI model was not valid in our cohort treated 
with rituximab with or without interferon. The PRIMA-PI on the other hand, although 
based on only two parameters – beta2-microglobulin and bone marrow involvement, was a 
useful tool in differentiating a small group of patients with very poor prognosis, that should 
be considered for a new or more intensive and hopefully more effective therapeutic 
approach. 
 
In paper IV we followed the changing composition of immune cells in blood in FL patients 
randomized to therapy with rituximab with or without lenalidomide. Cells were sampled at 
baseline, after 2 weeks of lenalidomide (combination arm), 24 hours after first rituximab 
dose and at follow-up weeks 10 and 23 and analysed by flow cytometry. With lenalidomide 
alone a transient increase in monocyte and NK cell fractions appeared, the latter decreasing 
again after first rituximab infusion. Post-treatment effects included an increased fraction of 
T cells as a group and an increased CD4/CD8 ratio. A high proportion of monocytes at 
baseline was associated with clinical response at week 10 as were a larger fraction of naïve 
T cells in the rituximab monotherapy treatment arm. Possibly lenalidomide may help 
overcome the negative impact of few naïve cells, by a beneficial effect on their activity. 
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1 INTRODUCTION 
 
1.1 OVERVIEW  
 
After the early description of Hodgkin’s disease, R. Virchow was the first to launch the 
term lymphosarcoma for the non-leukemic tumours later collectively named non-Hodgkin’s 
lymphoma (after dropping of the possessive form simply non-Hodgkin lymphoma, NHL). 
Many years followed, during which pathologists had only a vague idea of these presumably 
malignant conditions presenting with lymphadenopathy and splenomegaly and applied 
different terminology.1 In 1942, Gall and Mallory2 tried to bring order introducing a 
classification based on clinicopathologic criteria. During the years 1966-1976 the 
heterogenous entity of NHL was to be found in six different classification systems; the 
Rappaport3, Kiel4, Lukes-Collins, Dorfman, British, and World Health Organization 
systems.5 Starting in 1982, the Unites States (US) National Cancer Institute recommended 
the Working Formulation which was adopted in the US while an updated version of the 
Kiel classification was preferred in Europe. The Working Formulation and Kiel 
Classification were in 1994 replaced by the Revised European-American Lymphoma 
(REAL) classification6, which making use of scientific advances, included morphologic, 
immunophenotypic, genotypic, and clinical features into the definition of NHL subtypes.7  
 
Follicular lymphoma (FL) is characterized by a usually follicular (nodular) pattern of 
growth and earlier names for the disease reflected its appearance. It was termed nodular 
lymphoma in the 1956 Rappaport classification3 and with reference to cytology 
centroblastic/centrocytic lymphoma in the 1974 Kiel classification.4 In the REAL 
classification6 it was called follicular centre lymphoma because it is composed of 
centroblasts and centrocytes of the germinal centre in the follicle.8 The World Health 
Organization (WHO) classification of 20019 was built upon the REAL and has, including 
its revised editions, ever since been the international gold standard for all hematopoetic 
neoplasm. FL is hereby grouped among the mature B-cell malignancies of the NHLs.7 
Although a more accurately defined neoplasm within the adaptive immune system, FL is 
still a heterogeneous entity for which the clinical course is highly variable.8, 10, 11 
 
When Gall and Mallory presented their work in 1942, average survival after diagnosis of 
FL was around five years.2 Treatment often consisted of radiation over relatively large 
fields of the body in lower or higher doses depending on the aggressiveness of the disease, 
and/or surgical excision, later sometimes with the addition of chemotherapy.12-14 1946 saw 
the first publication on nitrogen mustard therapy15, cyclophosphamide was introduced into 
clinical practice in the late 1950s16 and treatment during the following decades came to 
include different chemotherapy regimens. In the 1990s steroids, the oral alkylators 
chlorambucil and cyclophosphamide, the purine analogue fludarabine and the combination 
of fludarabine, mitoxantrone (topoisomerase inhibitor) and dexamethasone (FND) were all 
common as first-line therapy, whereas in the relapse situation usually combinations of 
cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) were applied.17 When 
the anti-CD20 monoclonal antibody rituximab was introduced in the late 1990s, it 
significantly improved the prognosis for patients with all types of B cell lymphomas.  
 
The majority of FL patients respond well to therapy, but eventually relapse and generalized 
disease is still considered incurable. On the other hand, a substantial number of patients 
appear to have such an indolent disease that the benefit from treatment is unclear.8, 10 In the 
clinical setting one challenge is to identify patients in need of therapy upfront as opposed to 
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those who can be managed with active expectancy. The typical patient will during his or 
her lifetime receive a number of different therapies with variable intensity toxicity.10 
Factors that seem to be of importance for the course of disease apart from the clinical status 
of the host, are features of the tumour cells as well as the immune cells in the surrounding 
microenvironment. An increased understanding of the complex intra- and inter-cellular 
signaling provides new potential targets for therapeutical intervention.11 
 
1.2 EPIDEMIOLOGY 
 
Follicular lymphomas account for about 20% of all lymphomas with the highest incidence 
in the Unites States (US) and Western Europe where it is the second most frequent subtype 
among lymphoid malignancies.1 However, numbers vary between geographical regions and 
ethnic groups; compared to the age-standardized incidence of 2-4 per 100000 person-years 
in the US and Europe18, 19, FL in Japan and South Korea for instance is 2-3 times less 
common.8 Within the US, the lowest incidence 2011-2012 was reported in the minority of 
people with Asian or Pacific Island descent and second lowest in African Americans.18 In 
Sweden the estimated number of new patients each year is around 250.20 According to data 
from the National Cancer Institute, the FL incidence is slowly decreasing again after a peak 
in the year 2003.21 The reason for the decline is unknown but one hypothesis is the 
decreasing use of cigarettes.18 In addition to tobacco use and family history22, 23, Sjögren 
syndrome23, 24 (as opposed to other autoimmune diseases) and lifetime use of antibiotics25 
have been associated to an increased risk of FL. The median age at diagnosis is 60-65 years 
with a male:female ratio of 1:1.2-1.7.18-20, 26  
 
1.3 DIAGNOSIS OF FOLLICULAR LYMPHOMA - SUBTYPES  
 
FLs are composed of centroblasts and centrocytes growing in the follicles of lymph nodes, 
but also in spleen, tonsils and bone marrow. At diagnosis most patients have disseminated 
disease involving lymphoid tissue at various sites and occasionally, in addition or primarily, 
extranodal organs such as skin or testis.1 Yet, the typical patient is feeling well and does not 
always present with a palpable enlarged lymph node.8 In the current WHO classification, 
FLs are subclassified into grades 1, 2, 3A and 3B, according to the number of large 
immature centroblasts dispersed among the smaller more differentiated centrocytes, 
counted in 10 random neoplastic follicles and expressed per x40 high-power microscopic 
field (Table 1).27 Since histology varies among follicles, an adequate sample is crucial and 
fine needle aspiration alone insufficient for grading. The grading system and its clinical 
significance have been a matter of debate and no method has shown high reproducibility 
between pathologists.8, 28 Grades 1, 2 and 3A are considered indolent whereas 3B, by 
definition holding the greatest number of large cells, is more aggressive sharing features 
with diffuse large B cell lymphoma (DLBCL).28 In the latest WHO classification distinction 
between grades 1 and 2, the most frequent grades, is no longer recommended.8 
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Table 1. WHO Grading System for FL  
 
  
 
Follicular lymphoma (FL) is graded according to cytological features. CB, centroblast; HPF, high-power microscopy field 
(×40 objective, 0.159 mm2). Diffuse areas with >15 centroblasts per hpf are reported as diffuse large B-cell lymphoma. 
 
Rare variants of FL include duodenal-type FL and in situ follicular neoplasia (ISFN) where 
“in situ” refers to signs of FL restricted to one or more follicles in an elsewhere normal 
appearing lymph node. Compared to partial nodal involvement of FL, the in situ variant is 
less likely to progress. In the WHO 2016 revision pediatric FL as well as primary cutaneous 
follicle center lymphoma are recognized as separate entities not sorting under FL.27 
 
1.4 PATHOGENESIS 
 
The characteristic hallmark, present in up to 90% of FL, is the t(14;18) (q32;q21) 
translocation, an error occurring in the maturing B cell where the immunoglobulin heavy 
chain gene is juxtaposed to the anti-apoptotic gene B cell lymphoma/leukemia 2 (BCL2) 
leading to an overexpression of the latter. The process is initiated in the bone marrow and 
followed by migration of affected cells to germinal centers in lymph nodes where 
secondary events occur.29 The same t(14;18) translocation can be found in approximately 1 
per 105 of peripheral blood B cells in healthy individuals with a large inter individual 
variation but often increasing with age. It is also thought to be present in 2-3% of reactive 
lymph nodes. For a lymphoma to occur, a number of additional genetic alterations; 
mutations in chromatin modifiers among others, as well as certain interactions of the B cell 
with the microenvironment are needed. Due to its complexify the pathogenesis remains 
poorly understood (Figure 1). Several of the most frequently mutated genes (CREBBP, 
EZH2, KMT2D, MEF2B) may cause a maturation arrest at the proliferative stage of the cell, 
preventing it from differentiating into a memory or plasma cell. Like for normal B cells 
signaling downstream of the B cell receptor seems crucial for FL cell survival and retention 
of immunoglobulin expression is mandatory. The surface immunoglobulin is known to 
provide both a low-level tonic signal, perhaps from environmental autoantigens with 
interaction facilitated by mannosylation of the immunoglobulin binding-sites, as well as a 
true antigen-mediated signal, and their relative importance in FL cell survival is unclear.30 
Several studies have focused on FL with versus without the classical BCL2 breakpoint.31-32 
Leich et al.31 found that the BCL2 protein was expressed also in the majority of breakpoint-
negative cases, indicating that a mechanism other than t(14;18) leads to BCL2 expression. 
It is still unknown which events in the FL pathogenesis may compensate for the lack of 
BCL2 protein in t(14;18) negative cases. 
 
 
 
GRADING DEFINITION
Grade 1-2 0-15 centroblasts per hpf
1 0-5 centroblasts per hpf
2 6-15 centroblasts per hpf
3 >15 centroblasts per hpf
3A Centrocytes present
3B Solid sheets of centroblasts
PROPORTION FOLLICULAR PATTERN REPORTED
>75% Follicular
25-75% Follicular and diffuse
<25% Focally follicular
0% Diffuse
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Figure 1. Critical influences on the pathogenesis of FL (Adapted from Küppers et al. 2018) 
 
  
 
1.5 TUMOUR MICROENVIRONMENT 
 
Still after all, the FL cell itself much resembles the normal germinal centre B cell, 
morphologically, immunophenotypically and even genetically, and is surrounded in the 
tumour by various non-neoplastic cells such as T cells, follicular dendritic cells and 
macrophages.33 In 2004, Dave et al.34 demonstrated a correlation between features of the 
non-malignant immune cells in the diagnostic biopsy and patient survival and there has 
since then been increasing evidence that the microenvironment plays a crucial role in the 
development and progression of lymphoid malignancies. Several studies have been 
focusing on the complex signaling between tumour cells and non-malignant cells, where 
dendritic cells, monocytes/macrophages, mesenchymal stromal cells (MSCs) and the 
plasticity of helper T cells all play a part.35-38 In summary, a high overall content of tumour 
infiltrating T-cells, in particular CD8+ T cells, is prognostically favorable in contrast to 
tumour-associated macrophages (TAMs). Data on T-cell subsets including regulatory T 
cells (T regs) and T follicular helper (TFH) cells and their relation to prognosis and therapy 
are however conflicting.35-38 Not only the number of cell subsets but also their infiltration 
pattern seem to play a role, as well as their activity and expression of surface molecules 
such as programmed death-1 (PD-1). PD-1 is involved in T cell function and its expression 
can reduce the anti-tumour response.35  
Factors underlying a more aggressive course may be either primary genetic changes in the 
tumor cells or variability in the host immune response.29 Clearly chromosomal aberrations 
and mutations in genes in the neoplastic cell, including the tumour suppressor gene TP53, 
are associated with aggressive disease26 and are likely to promote a microenvironment 
further supporting tumor growth as well as suppressing anti-tumoral response.29, 39 
 
1.6 PROGNOSTIC MODELS 
 
In general the indolent lymphomas progress slowly and the prognosis for patients with all 
types of CD20+ lymphoma improved with the introduction of rituximab, the median 
survival for follicular lymphoma patients across clinical stages, now reaching nearly 20 
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years from time of diagnosis.40 However, although FL grades 1-3A are all considered to be 
indolent lymphoma their clinical course is highly variable. Some patients, also with 
disseminated disease at diagnosis, remain asymptomatic for many years without any sign of 
lymphoma progression and even spontaneous remission41, whereas others early undergo 
transformation to high-grade disease; 3B or DLBCL. In contrast to FL grade 3B which is 
treated with intensive chemotherapy with a curative intent, the lower grades are still 
considered incurable unless strictly localized and thereby possibly eradicated with 
radiotherapy.28 Also in the rituximab-era, lymphoma progression has sometimes been 
shown to be the leading cause of death in all age-groups during the first decade after 
diagnosis, followed by treatment-related mortality.42 
 
Traditionally, a lower grade was thought to mean better prognosis26 but more recent data 
show that in patients given rituximab as first-line therapy, those with grade 3A survive 
longer than those with grade 2, and grade 2 patients have better survival than do grade 1.43-
44 Proliferation is not included in the grading criteria, but may be associated with grade as 
well as with prognosis as cases with high proliferation index often behave more 
aggressively. However, as with grading, interobserver variability cannot not be disregarded 
nor can the proliferation, as estimated, of the surrounding T cells.45 
 
The optimal timepoint, choice and sequence of therapeutic regimens remain matters of 
debate 46-48 and is one major challenge for the treating physician to decide upon. Several 
attempts have been made to find a way of predicting the clinical course49-50 but so far none 
has proven a useful tool in guiding therapeutic intervention. In 2004 the clinical Follicular 
Lymphoma International Prognostic Index (FLIPI)49 was presented and it has since then 
become widely used. It is based on data from patients before rituximab was introduced and 
includes age, clinical Ann Arbor stage51, hemoglobin and lactate dehydrogenase levels and 
number of affected lymph node stations according to a specified anatomical map, with 
overall survival (OS) as endpoint. However, among clinicians and radiologist the 
assessment and calculation of areas of lymphadenopathy has not always been 
straightforward (Figure 2). In 2009, the FLIPI was revised by Federico et al.50 who 
introduced the FLIPI2 including slightly different baseline variables such as serum beta2-
microglobulin and bulky disease defined as a largest tumour diameter of > 6 cm. The 
FLIPI2 was developed in patients treated with chemotherapy, some with the addition of 
rituximab and its primary endpoint is failure-free survival (FFS) instead of OS. Still the 
FLIPI2 model is used less than the FLIPI, perhaps because many centres do not include 
beta2-microglobulin in their routine blood analyses and because of the required 
measurement of lymphatic mass (Table 2). 
 
 
 
Table 2. FLIPI and FLIPI2 variables 
 
 
 
FLIPI FLIPI2
Age, years > 60 > 60
Hb < 120 g/l < 120 g/l
Serum marker LDH > ULN ß2m > ULN
Lymph node Nodal sites > 4 Size > 6 cm
Stage III - IV Bone marrow+
Low risk, 0 to 1; Intermediate risk, 2; High risk, 3 to 5.
RISK FACTOR
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Figure 2. Nodal stations according to FLIPI 
 
 
 
More recently the impact of a number of gene mutations in the tumour was evaluated by 
Pastore et al. in the m7-FLIPI prognostic model, derived from the FLIPI score combined 
with Eastern Cooperative Oncology Group (ECOG) and the mutational status of seven 
specific genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP, CARD11). Patients 
with FL were stratified into “low-risk” and “high-risk” with respect to their 5-year FFS 
after first-line immunochemotherapy (R-CHOP or R-CVP), according to a sum of predictor 
algorithm. Mutation in EZH2 gene, coding for the catalytic subunit of a histone 
methyltransferase, was found to be associated with better prognosis.52 Perhaps the most 
simple scoring system is the newly introduced PRIMA-prognostic index (PRIMA-PI), 
taking into account only bone marrow involvement and level of beta2microglobulin both as 
dichotomous variables. Based on the prospective PRIMA trial cohort treated with 
immunochemotherapy53 it divides patients into three risk categories of subsequent 
progression-free survival (PFS).54 As opposed to the FLIPI, FLIPI2 and m7-FLIPI, the 
PRIMA-PI does not include high age per se as a risk factor. Alig et al. reporting on the 
impact of age and genetics in FL conclude age itself should not guide treatment decisions.55 
 
Apart from patient baseline characteristics their future risk profile can be based on the 
course of disease, the depth and duration of therapy response. Data from the National 
LymphoCare Study showed that relapse of FL within 24 months of first-line 
chemoimmunotherapy is associated with very poor OS, establishing the concept of POD24 
as progression of disease status at 24 months.56 Shi et al.57 analyzed data from 13 
multicenter trials and found the remission status at 30 months after induction therapy 
(CR30); chemotherapy, immunotherapy and chemoimmunotherapy likewise, serve as a 
surrogate marker for progression-free survival. This is of interest as early identification and 
intervention in patients with poor prognosis might help improve both progression-free and 
OS. Baseline metabolic tumor volume (TMTV) assessed by fluorodeoxyglucose-positron 
emission tomography (FDG-PET) scan has been shown a strong predictor of PFS and OS58, 
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as has the remaining metabolic activity after induction immunochemotherapy.59, 60 Like the 
finding on PET scan, bone marrow involvement at baseline and after therapy measured as 
minimal residual disease (MRD) levels of BCL2/IgH(+) cells by real-time quantitative 
polymerase chain reaction (RQ-PCR) has been shown associated with prognosis61 although 
not as strongly as the in the case of PET.60 
 
1.7 TRANSFORMATION 
 
During the course of the disease some patients with FL acquire additional genetic 
aberrations thereby transforming to a highly malignant lymphoma, most often diffuse large 
B-cell lymphoma (DLBCL) but sometimes Burkitt lymphoma or lymphoma with features 
intermediate between these two or lymphoblastic lymphoma. In rare cases blast 
transformation occurs and the patient develops acute B-cell lymphoblastic leukemia. 
Histologic transformation from indolent to aggressive lymphoma is reported to occur in 10-
30% of FL patients over time at a rate of 2-3% per person-year and is known to confer a 
much worse prognosis than de novo DLBCL26. However, recent studies indicate that the 
prognosis for transformed FL (tFL) has been improved in the rituximab era62-65 and that the 
risk of transformation has slightly decreased.66 
 
The process of transformation was first described by Gall and Mallory2 nearly 80 years ago 
but similar to FL pathogenesis, it is still poorly understood. One problem when studying 
tFL is the different definitions used among the published series, including clinical, 
histological and cytological criteria. The gold standard definition is the most conservative 
and is based solely on histological criteria. For statement of a completely true 
transformation, a clonal relationship with the original FL should be demonstrated.67-68 
However, as a biopsy large enough to verify this is not always achieved, a definition of 
clinical transformation has been proposed. Clinical suspicion of transformation is raised 
when a patient with known FL presents with a rapid progression of lymphadenopathy, 
engagement of extranodal sites, B symptoms and/or elevated serum LDH.69 What also 
accounts for the wide variation in findings on incidence and outcome for patients with 
transformed disease, are beside the diagnostic procedures applied, the follow-up time of the 
studies. Moreover, in survival analyses death as a competing risk is not always taken into 
consideration although advisable. 
 
It was usually assumed that transformation occurs within a FL cell but more recent research 
with genomic hybridization and nucleotide polymorphism data suggest instead a common 
progenitor cell (CPC) to be the origin, giving rise to a related but distinct population of 
malignant cells.63, 70-71 Many studies have tried to find genes and/or protein products 
associated with transformation.72 None of the classical actors p53, BCL2 nor BCL6 seem to 
play a crucial role, perhaps more so the transcription factors MYC and NF-kB in the B cell 
receptor downstream signaling pathway.63 Steen et al. did propose a clinico-molecular 
predictor of transformation risk, the BTK-FLIPI, based on a gene expression score at 
diagnosis capturing deregulation of the NF-κB pathway.73 
 
In the evolution of transformation also the tumour microenvironment has been shown 
important. CD14+ dendritic cells and PD1+ T cells in a particular arrangement are 
associated with shorter time to transformation, as are increased intrafollicular levels of 
macrophages and CD4+ T cells, and an extrafollicular or diffuse localization of FOXP3+ 
regulatory T cells.74 To conclude, the transformation process is complex, seemingly 
influenced by genetic alterations and crosstalk with the microenvironment and possibly 
with the therapeutic regimen applied.75, 76 
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1.8 THERAPY 
 
1.8.1 First-line treatment 
 
In the minority of patients with strictly localized disease, radiation alone renders an 
estimated 50% chance of cure and long-term follow-up of these patients suggests a 10-year 
OS of up to 80%.48, 77 When patients with generalized disease are asymptomatic watchful 
waiting may well be considered as there is no documentation that early or intensified 
chemotherapy will prolong life.78-80 In a large randomized trial by Ardeshna et al.78 on FL 
patients with low tumor-burden stages II-IV asymptomatic disease, rituximab alone as 
induction therapy was shown to improve PFS compared to “wait and watch” but to have no 
effect on OS. Similar results were later achieved by an observational LymphoCare study.81 
Tools to determine which patients with disseminated disease are likely to benefit from 
immediate therapy are the Group Étude des Lymphomes Folliculaire (GELF) critera82 and 
the British National Lymphoma Investigation (BNLI) criteria.79 Still, patient and doctor 
preferences, local traditions as well as economic considerations may influence the timing of 
therapy initiation and choice of regimen, apart from comorbidities and potential side 
effects.  
 
When patients with FL first start treatment they usually respond well. Before rituximab was 
gradually introduced in clinical practice, in Sweden during the years 2003-200720, almost 
all received chemotherapy with little variation.10, 83 Since then, a number of regimens with 
different schedules have been tried, often combining an anti-CD20 antibody with one to 
three well-known cytostatic substances but also with antibody given as single agent or 
linked to a radioactive isotope.84-91 So far rituximab maintenance has shown no benefit over 
monotherapy retreatment at progression in patients with low-tumour burden.89 On the other 
hand the PRIMA randomized trial53, enrolling 1135 high-burden patients, found 
progression-free survival improved with rituximab maintenance after frontline therapy with 
rituximab and chemotherapy, and as a consequence two years of maintenance became the 
standard of care after rituximab with cyclophosphamide, doxorubicin, vincristine and 
prednisone (R-CHOP). However, a long-term follow-up demonstrated no effect of 
maintenance on OS.92 In patients perceived in need of chemotherapy practice has changed 
only these last years after the trial by Rummel et al.93 to rituximab combined with 
bendamustin (R-Benda) without maintenance, a regimen with milder haematological 
toxicity, fewer infections and less peripheral neuropathy than the R-CHOP. Interestingly, 
lenalidomide, a thalidomide derivative, was recently in the large multicenter RELEVANCE 
trial shown to be as effective in combination with rituximab as the R-chemo combination, 
in patients with previously untreated high tumour-burden FL.94 
 
1.8.2 Relapse treatment and new drugs 
 
Due to the relapsing nature of the disease and the well-known side-effects of chemotherapy 
more and more research has been focusing on new antibodies as well as on 
immunomodulatory agents such as lenalidomide, BCL2 inhibitors, PI3 kinase inhibitors, 
Bruton tyrosine kinase inhibitors and epigenetic modifiers as monotherapy or in 
combination regimens.77 The humanized anti-CD20 antibody obinutuzumab is currently 
recommended in the case of rituximab-refractory disease.95 As BCL2 seems strongly 
connected to the pathogenesis of FL there was much hope for its selective inhibition with 
the drug venetoclax, however clinical results have been modest.96-97 The Bruton tyrosine 
kinase inhibitor ibrutinib soon became standard of care for patients with chronic 
  9 
lymphocytic leukemia (CLL) with deletion 17p but for FL more promising results have 
been achieved with inhibitors of PI3 kinase isoforms such as idelalisib although there have 
been problems with toxicity.98-100 Inhibition of immune checkpoint interaction between PD-
1 and PD-L1 is another target mechanism for novel drugs, as it is important for the ability 
of tumor cells of evading the immune system. Blockade of PD-1 on T-cells in FL has been 
shown to promote their antitumor function.101, 102 Both PD-1 blockade and adoptive cell 
therapy (CAR-T cells) have shown promising results in smaller clinical trials.103, 104 Despite 
the rapidly growing arsenal of new drugs, autologous stem cell transplant (auto-SCT) is 
often recommended in younger patients with aggressively relapsing or transformed FL.105-
107 Allogeneic stem cell transplant (allo-SCT) is the only known potential cure for indolent 
lymphoma and may be considered, especially in the case of relapse after auto-SCT.105, 107, 
108 
 
Newer biological agents are likely to affect the significance of prognostic markers and 
scoring systems developed in the context of chemotherapy. This has been shown e.g. in the 
case of rituximab.109 A related field of research is the optimal method of evaluating therapy 
response, where the use of PET scans, immunohistochemistry and flow cytometry have 
increased. The well-established Cheson criteria110 were based on tumor volume not 
metabolic activity, prompting a revision presented in 2007 incorporating PET and flow 
cytometry. The revised criteria also included more precise definitions of endpoints such as 
progression-free survival and response duration which are, however, still being used 
without consistency in the literature. There is ongoing discussion about the value of 
molecular detection of MRD in blood and bone marrow but so far it has not been 
recommended outside of clinical trials.111, 112 
 
In summary, in light of the large number of therapeutical options available for patients with 
indolent lymphoma one may conclude so far none has proven the optimal solution for all. 
Questions on what to do, at what time and for whom are yet to be answered one at a time. 
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2 AIMS 
 
 
The overall aim of this thesis was to gain increased insight in clinical and immunological 
factors of predictive value and prognostic importance in a given therapeutical setting, in 
indolent lymphoma in general and in follicular lymphoma in particular. More specifically, 
we aimed at: 
 
1. Exploring the long-term outcome after immunotherapy given first-line and discover 
determinants for OS. 
 
2. Investigating the validity and usefulness of the two prognostic models; the 
clinicogenetic m7-FLIPI and the simplified two-parameter PRIMA-PI in patients 
treated with a chemo-free first-line regimen.  
 
3. Increasing our understanding of the effects on immune cells during the course of  
immunotherapy and identifying any relation to therapy response.  
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3 PATIENTS AND METHODS 
 
3.1 STUDY POPULATION 
3.1.1 Papers I-III 
 
Papers I-III were all based on a larger study population of 439 patients included in either 
one of two consecutive Nordic Lymphoma Group (NLG) randomized clinical trials; 
M39035 with accrual 1998-1999 (n=126) and ML16865 with accrual 2002-2008 
(n=313).85, 86 The overall aim of both trials was to deliver effective treatment without the 
well-known short- and long-term complications of chemotherapy. Patients with the 
diagnosis of an indolent B-cell lymphoma and generalized symptomatic disease were after 
biopsy review randomly allocated to treatment with single rituximab or rituximab combined 
interferon-α2a (IFN). The treatment was first-line for all except a minority who had 
previously received local radiation and/or a short course of chlorambucil. Therapy 
consisted of 4 weekly doses of rituximab (375 mg/m2) and in case of randomization to IFN, 
IFN- α2a 3 MIU/day subcutaneously (sc) week 1, followed by 4.5 MIU/day sc weeks 2-5 
(Figure 3). 
 
 
 
Figure 3. Flow charts of trials M39035 and ML16865. Each gray rectangle symbolizes a weekly 
dose of 375 mg/m2 rituximab and each black zigzagged line represents IFN of 3 MIU/d daily 
during week 1 and 4.5 MIU/d) during weeks 2 through 5, except on rituximab days. EV-1 and EV-
2, signify first and second treatment response evaluation. 
 
 
 
IFN = interferon-α2a. SD = stable disease. PD = progressive disease. CR = complete response. PR = partial 
response. MR = minimal response. 
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In paper I was included a subgroup of the in total 439 patients treated within the two trials. 
All Swedish, Norwegian and Danish patients with FL, marginal zone lymphoma (MZL), 
small lymphocytic lymphoma (SLL) or indolent lymphoma not otherwise specified (NOS) 
were eligible for the long-term follow-up provided they had previously received neither 
radiotherapy nor chlorambucil. Patient inclusion in paper II was based on the diagnosis of 
FL or indolent lymphoma NOS (presumably indolent FL without enough material for 
grading) and most importantly the availability of fresh-frozen biopsies with sufficient 
material for gene sequencing. As opposed to paper I, also a few patients who had received 
radiotherapy/chlorambucil were included. Paper III was based on all patients in paper I 
with FL or indolent lymphoma NOS. In conclusion, there was a partial overlap between the 
study populations of papers I-III. 
 
3.1.2 Paper IV 
 
Like papers I-III, paper IV was based upon a randomized clinical trial, this time evaluating, 
first-line treatment with single rituximab and the combination with lenalidomide (Figure 4). 
Then multicenter SAKK3510 trial was a collaboration between the Swiss Group for 
Clinical Cancer Research (SAKK) and the NLG with accrual 2012-2014 and with clinical 
results published in 2019.113 Among the 154 patients included in the SAKK3510, 36 
patients from Norway and Sweden took part in the translational project and provided 
consecutive blood samples at up to five times each before therapy, during the course of 
treatment and after. All had received infusions of rituximab at weeks 1, 2, 3 and 4 followed 
by 4 additional at weeks 12, 13, 14 and 15, with or without lenalidomide 15 mg p.o. daily 
starting week -2 and ending at week 17. 
 
 
 
Figure 4. Trial design of the multicenter SAKK3510 
 
CR = complete response. PR = partial response. 
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3.2 DATA COLLECTION 
 
3.2.1 Papers I-III 
 
For paper I, a case report form (CRF) for collection of clinical follow-up data was created 
and distributed to the centres earlier participating in the two clinical trials. Variables 
assessed included all post-trial therapies with types and dates of initiation, infectious 
complications, transformation to high-grade disease and occurrence of second primary 
malignancies. For live patients, dates of last follow-up were noted and for those deceased, 
the dates and causes of death. Information on diagnosis, sex and age and other clinical 
variables at the time of inclusion in the randomized trials was retrieved from the original 
study databases. For papers II-III, relevant data were retrieved from the new database 
created for paper I. In some centres there was no co-investigator in charge at the time of the 
long-term follow-up, in which case a local temporary permission for external record review 
was obtained. The variability between investigator access to medical files was reflected in 
the varying amount of detailed information provided in the new data compilation. The gene 
sequencing in paper II was performed by means of a targeted panel including the seven 
genes of the m7-FLIPI: EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP and CARD11 
and the m7-FLIPI score for each patient was calculated according to the published 
algorithm.  
 
3.2.2 Paper IV 
 
FL patients were sampled at baseline before therapy initiation, after 2 weeks’ of 
lenalidomide (in patients with combination treatment), 24 hours after first rituximab dose 
and at follow-up weeks 10 and 23. Fresh whole blood in EDTA tubes was shipped from 
participating centres to Stockholm immediately after sampling and analysed by flow 
cytometry, gating upon mononuclear cells and lymphocytes respectively, after the 
exclusion of doublets and debris. Response data were provided from CRFs and CT scans, 
reevaluated by the chairs of the SAKK3510 trial. 
 
3.3 DEFINITIONS OF ENDPOINTS AND GROUPS 
 
3.3.1 Papers I-III 
 
OS, the main endpoint in paper I, was estimated from the date of randomization in the 
original trials to death, or end of follow-up in which case patients were censored. The 
secondary endpoint Time to New Anti-Lymphoma Therapy (TTNT) was considered 
equivalent to and more robust than Time to Progression (POD). Outcome measures 
included also Time to New Anti-Lymphoma Therapy restricted to chemotherapy-containing 
regimens (TTNChemo), Time to Transformation (TTT) and Lymphoma-Specific Survival 
(LSS). Time to treatment failure (TTF), the primary endpoint of papers II-III, was defined 
as the interval between start of trial therapy and either initiation of new lymphoma therapy 
due to relapse or intolerance, or death from any cause. The Pastore cut-off score of ≥ 0.8 for 
discrimination between the m7-FLIPI high- vs low-risk group was applied in paper II. In 
paper III patients were classified into the three FLIPI risk groups (low: 0-1, intermediate: 2 
and high: 3-5 risk factors)49 and into the three PRIMA-PI categories: high-risk: ß2-
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microglobulin (ß2m) > 3mg/L, intermediate-risk: ß2m ≤ 3 mg/L with bone marrow 
involvement and low-risk: ß2m ≤ 3 mg/L without bone marrow involvement.54 
 
3.3.2 Paper IV 
 
Complete response/unconfirmed (CR/CRu), partial response (PR), stable disease (SD) and 
progressive disease (PD) were assessed according to the Cheson 1999 criteria.110 The week 
10 evaluation made use of an additional response category called minor response (MR), 
defined as a >25% but <50% decrease in sum of product of diameters (SPD) of affected 
lymph nodes. 
 
3.4 STATISTICAL ANALYSES 
 
In all papers the significance level was set to 0.05 and all tests were two-sided. 
 
3.4.1 Papers I-III 
 
Survival across subgroups was analyzed with log rank test and graphically presented in 
Kaplan-Meier curves. A Cox regression model was used for estimates of hazard ratios both 
crude and adjusted for independent predictors as described. Patients were censored at last 
follow-up without event. 
 
3.4.2 Paper IV 
 
The Wilcoxon signed-rank test was applied for comparing changing fractions of cell 
subsets between any time point and baseline, and the rank-sum test for levels between 
treatment arms. Kruskal-Wallis and Fischer´s exact tests were used for evaluation of cell 
subsets as continuous variables as well as predictors dichotomized by the median, in 
relation to the binary outcome of response vs non-response. 
 
3.5 ETHICAL ASPECTS 
 
The three original randomized trials M39035, ML16865 and SAKK3510 upon which this 
thesis is largely based, were performed in accordance with good clinical practice (GCP) and 
approved by the ethical committees in each participating country. All patients had given 
their informed written consent to the intervention as well as the clinical and translational 
investigations associated. In preparation for papers I-III renewed ethical permissions were 
obtained from the regional ethical committee of Stockholm and patients who were still alive 
were asked for renewed consent regarding extensive medical file review but no family of 
deceased patients were contacted. In paper II tissue samples already extracted and saved 
were further analyzed with respect to genetic aberrations but only genes thought to be of 
importance to course of lymphoid disease were assessed and contacting all these patients 
once again was considered neither appropriate nor necessary. As the flow cytometry 
analyses of paper IV were included in the approved protocol and patient information of the 
SAKK3510 clinical trial, no more permits were asked for.  
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Although all data are presented only at the group level, the risk that some patients would 
disapprove of the refined laboratory analyses or thorough review of medical files cannot be 
completely ruled out.  
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I 
 
Our study of first-line rituximab without chemotherapy in indolent lymphoma illustrates 
that after a median follow-up of 9.8 years, 3/4 of patients can be expected to be alive. This 
is at least as good as the OS observed in several modern immunochemotherapy trials such 
as the recently reported long-term results of the PRIMA trial and other follow-up studies.92, 
114-117 The duration of those immunochemotherapies, some also with rituximab 
maintenance, was longer and toxicities were higher than in our chemotherapy-free 
therapies. We here find that a substantial proportion of patients (36%) will perhaps never 
require any chemotherapy with its known early and late side effects. In our study 30% of 
FL patients required no second-line therapy at all. Surviving patients had a median follow-
up time of 10.6 years. 
 
As OS of patients with indolent lymphoma improves, the burden of late side effects 
becomes of greater concern. In other rituximab trials, most of them including also 
chemotherapy, late complications have been reported including heart failure, LON, 
intestinal perforation, interstitial pneumonitis, reactivation of viral infections e.g. herpes 
and hepatitis and the uncommon but severe progressive multifocal leukoencephalopathy.118-
120 Several studies suggest an increased overall risk of a second primary cancer after 
treatment for lymphoma121-126 but it is unclear whether this is due to the treatment 
(chemotherapy, immune suppression) or inherent to the patient group with shared genetic 
and/or environmental etiology. A meta-analysis by Fluery et al. showed no such increased 
risk from rituximab alone after a median follow-up of six years.127 As many patients in our 
study had received additional lines of therapy, the potential benefit of first-line 
rituximab/IFN alone is difficult to evaluate, but the chemotherapy-free approach is 
suggestive of a slightly reduced risk of LON, viral reactivation and second primary 
malignancies. Moreover, omitting the cardiotoxicity of anthracycline and the neurotoxicity 
of vincristine do reduce the risk of heart failure and peripheral neuropathy.128-130As very 
few studies report on follow-up beyond 10 years, comparisons of late secondary outcomes 
remain hypothetical.  
 
The 10-year cumulative incidence of transformation of 20% at a rate of 2.4% per person 
and year observed in our study is broadly similar to what has been previously described for 
FL.62-65, 116, 126, 131 Management strategies including watch and wait in asymptomatic 
indolent disease, genotoxic chemotherapy and rituximab maintenance, may influence not 
only the risk but also outcome of transformation.78, 62-64, 132 Our results are in line with 
recent data, suggesting that the risk of transformation in the immunotherapy era has been 
well reduced from a 5-year cumulative incidence of nearly 20% pre rituximab, and survival 
following such an event improved from a median of 0.6-2.7 years.62, 69,126 Of note, our data 
suggest a relatively constant transformation rate over time with no plateau within 15 years 
from initial lymphoma diagnosis. 
 
The prognostic value of FL grading27 has been debated.133-234 In our cohort with biological 
therapy the survival of patients with FL grade 1 was inferior to that of higher grades, in line 
with some previous reports109, 135, 136 but not with all.137 B cell lymphoma sub diagnostics 
being sometimes complex, the higher transformation risk in the non-follicular lymphoma 
group may in part be due to a number of indolent lymphomas NOS cases in fact 
representing FLs with more diffuse growth patterns.  
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As in the LymphoCare Study by Castulo et al, FL patients with progress within 24 months 
of first-line therapy had a poor OS27 but the OS for our patients with early POD was better. 
This is likely due to the several salvage treatments, including chemotherapy, remaining 
available after a first-line therapy with little toxicity. 
 
4.2 PAPERS II-III 
 
In the report by Pastore et al. patients with low-risk m7-FLIPI score clearly outnumbered 
those with high-risk m7-FLIPI, an imbalance that was even more pronounced in our study 
cohort where only 17 out of 95 patients had a high m7-FLIPI score. Unlike what was 
reported by Pastore et al on FL patients´ 5-year FFS after first-line immunochemotherapy 
(R-CHOP or R-CVP), the m7-FLIPI prognostic model was not able to discriminate 
between “low-risk” and “high-risk” patients. No difference in TTF nor OS was found 
between our two m7-FLIPI risk groups. Still, our earlier finding of an existing but weaker 
association between POD24 and OS after first-line immunotherapy14 compared to what was 
shown after R-CHOP27, suggests that the m7-FLIPI model likewise might have a somewhat 
predictive value also in the non-chemotherapy setting. 
 
Mutation in the EZH2 gene, coding for the catalytic subunit of a histone methyltransferase, 
was here associated with longer TTF only in univariate analysis. This is different from the 
independent association shown in the Pastore report and in the report by Stevens et al. on 
end of spectrum FL patients treated with immunochemotherapy.138 Most surprising and 
remarkable was the finding of EP300 as a very clear indicator of inferior outcome in our 
cohort, stronger than previously reported to our knowledge. These findings are suggestive 
of other mechanisms involved in the antitumoral response to antibodies and/or 
immunomodulators than to agents of chemotherapy. 
 
The simplified PRIMA-PI, based only on serum beta2-microglobulin and bone-marrow 
lymphoma infiltration, had a prognostic value for TTF as well as for OS in our FL cohort 
with first-line chemo-free therapy, The OS rate, both at 5-and 10-years, was lower in the 
PRIMA-PI high-risk group than in the FLIPI high-risk group. Thus, the PRIMA-PI better 
than FLIPI identified the small group of FL patients (19% of all) with a true poor prognosis 
(Figure 5), although not as poor as that of the 32% high-risk patients in the study of Bachy 
et al.54 The model might serve as a tool for stratification of patients upfront and for 
selection of those likely to benefit from more intensive management, including all patients 
with high ß2m who by definition are high-risk irrespective of bone marrow results. For 
patients with low and intermediate PRIMA-PI chemo-free therapy remains an option as the 
10-years OS rate was 82% and 78%, respectively, and for patients responding to the first 
cycle the OS even higher (94 and 80%, respectively). 
 
 
Figure 5. PRIMA-PI and FLIPI high risk groups 
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Both in the NLG rituximab-interferon trials and in the SAKK3510 trial response was 
independent of FLIPI. Recently results have been published from the RELEVANCE and 
the SAKK3510 trial,94, 113 indicating that a non-toxic regimen with rituximab and 
lenalidomide even with short duration and without maintenance often can induce durable 
responses as the drug effects seem synergistic.139 Perhaps the PRIMA-PI prognostic tool 
will turn out more valuable than the FLIPI in the chemotherapy-free setting. 
 
4.3 PAPER IV 
 
With lenalidomide alone a transient increase in monocyte and NK cell fractions was found, 
the latter decreasing again after first rituximab infusion, which might be due to either 
consumption in ADCC and/or homing to tumour sites, an idea suggested by others.140, 141 
A few patients had very high baseline levels of CD19+CD20+ suggestive of a leukemic 
component. Overall, the B cell fraction started to decrease already after 14 days with 
lenalidomide treatment (p=0.0029) and was fully depleted in both treatment arms 24 hours 
after first rituximab infusion. T cells on the other hand first decreased with lenalidomide but 
increased over time in both treatment arms and remained elevated. The relative increase in 
total T cell fraction and other immune cell populations could be only partly due the decline 
in B cells which takes place very soon after therapy initiation. Numerically, B cells are too 
few in blood to allow such a great increase to be explained only by their replacement. 
Moreover, the changing NK to T cell ratios, as well as monocyte to T cell ratios, are 
evidence of processes ongoing irrespective of concomitantly diminishing B cells. 
 
Treatment effects sustained at week 23 included an increased CD4/CD8 ratio. This was due 
to a large rise in CD4 counts and a less pronounced rise in CD8 counts. A high percentage 
of monocytes and naïve CD8+ above the median at baseline were suggestive of week 10 
response, which is in line with other reports where a larger fraction of naïve T cells at 
baseline were positively associated with response to therapy.142-144 We found that the 
difference in response between higher and lower fractions were often more pronounced, 
although not always significant, in the rituximab monotherapy treatment arm. This could 
possibly be due lenalidomide helping overcome the negative impact of, e.g. few naïve T 
cells, by a beneficial effect on their activity, in analogy with the results presented by 
Wahlin et al. demonstrating an abrogation by IFN-α2 of the negative impact of few CD8+ 
cells.145  
 

  23 
5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
5.1 CONCLUSIONS 
 
5.1.1 FL grade 1 
 
FL grade 1 is a distinct subentity of FL just like FL grade 3b. In the rituximab era FL grade 
1 seems associated with slightly worse prognosis than do grade 2 and 3a, in patients treated 
with immunotherapy and possibly in those receiving combined immunochemotherapy. 
 
5.1.2 Risk assessment 
 
The therapeutic regimens available in follicular lymphoma is a growing field and PFS as 
well as OS after diagnosis are both improving. Due to the often indolent course of disease 
long-term effects including OS hard to assess. Many studies have been conducted in the 
search of earlier accessible surrogate markers and endpoints such as event-free survival 12 
and 24 months from diagnosis, or 30 month complete response (CR30)57, 146  Papers I, II 
and III all support the hypothesis of markers and scores having different prognostic value 
in different therapeutic settings. 
 
5.1.3 The chemo-free approach 
 
Also among FL patients in symptomatic advanced-stage disease, a substantial number will 
achieve long remission with immunotherapy only, a therapeutic approach with usually 
milder side-effects. It is therefore worth considering and can in many cases be given a try 
under close monitoring. Any non-responding patient would soon be shifted to salvage 
therapy. The decision to start therapy in general and chemotherapy in particular, should be 
based on the presence of symptoms, comorbidity and disease progression or transformation. 
Quality of life issues, possible infectious complications and the risk of secondary 
malignancies are all to be taken into consideration when making treatment decisions. 
 
5.1.4 Lenalidomide 
 
The immunomodulation exerted by lenalidomide and the antitumoral effects of rituximab 
and lenalidomide in combination are reflected in the immune cell dynamics not only in 
lymphnodes but also in blood. This is evident already after 14 days of lenalidomide 
monotherapy. The distribution of immune cells before therapy initiation, and the following 
change in constitution, seem to be associated with anti-tumoural response. 
 
5.2 FUTURE PERSPECTIVES 
 
FL is most common in the western world, which should be due to a combination of genetic 
and environmental factors. Of the two, genetics is the more fixed whereas environment can 
change rapidly. Although FL incidence seems to have reached a plateau in the US and 
western Europe, it is likely to continue growing in other parts of the world as countries 
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adopt a more western lifestyle exposing their people to new/other carcinogens. As people 
move around the world and their nutritional, occupational and leisure habits tend to blend 
with the aid of internet and new social platforms, regional differences in disease panoramas 
start to fade. 
 
Future studies will increase our understanding of FL pathogenesis at the molecular level. 
This will not only give us new targets for therapeutical intervention but also provide 
frameworks for diagnosis and classification of subtypes and variants. Perhaps in a future 
WHO classification we will see follicular lymphoma not to be one entity but several, some 
of them with new names. 
 
Advances in the field of genetics will facilitate a more personalized approach to risk 
assessment and treatment. Germline polymorphisms as well as the mutational profile of the 
malignant cells will to a larger extent guide our choice of drugs and their dosage for the 
individual patient. 
 
Many new drugs effectively target the interaction of the microenvironment and the immune 
system with the tumour. In addition, current regimens such as autologous and allogeneic 
stem cell transplants will be performed, in selected patients and perhaps in a modified way, 
with improved results. Overall prognosis will continue to improve but new drugs will 
expose us to yet unknown side effects. Economic issues will become of increasing 
importance and as a consequence ethical issues need to be discussed. 
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